Pfizer Beats and Raises Guidance While Shopify Misses Revenue for the First Time Since 2022 — November 3 Earnings in Two Acts

Tuesday morning gave investors a perfect earnings contrast: Pfizer beat expectations on both sales and profit and raised its full-year guidance, while Shopify grew revenue 32% — and still fell about 16% before the open, because its revenue missed by a whisker for the first time since 2022

Both companies reported before the opening bell on November 3, 2026, and both sets of numbers were strong in absolute terms. That is precisely why the pair is instructive. Earnings season does not reward "good" in the abstract; it rewards "better than the number the market already priced in." Pfizer cleared its bar with room to spare and lifted its outlook. Shopify cleared its profit bar, grew fast, generated more cash — and missed the two numbers traders watch most closely, revenue and subscription sales, by small margins. The market's verdict was immediate and opposite. Understanding why both reactions make sense is the whole lesson of this earnings morning.

1. Pfizer: a beat on both lines, and a higher bar for the rest of the year

Pfizer reported third-quarter revenue of $16.58 billion, above analyst expectations of about $15.87 billion, while adjusted earnings reached $0.87 per share against expectations of about $0.73. Reported diluted EPS, however, declined 9% to $0.56, while net income fell 8% to $3.24 billion — a reminder that adjusted and reported earnings tell different stories, and the gap here reflects charges including a $650 million research-and-development charge tied to its Innovent Biologics licensing agreement. The commercial drivers were familiar and reassuring: strong demand for Eliquis and oncology medicines, particularly Padcev, helped offset declining COVID-19 product sales. Sales of non-COVID products increased 7% on an operational basis, and revenue from recently launched and acquired products surged 32% on the same basis. Then came the part the market most wanted to hear: Pfizer raised its full-year 2026 revenue guidance to $62–64 billion, from $60.5–62.5 billion, and raised and narrowed adjusted EPS guidance to $2.95–$3.05, from $2.80–$3.00. A beat plus a raise is the cleanest signal a company can send in earnings season, and Pfizer delivered both — even as the longer-term challenge remains replacing revenue exposed to patent expirations, including Eliquis and the cancer medicine Ibrance.

2. Shopify: 32% growth, record-ish cash — and a miss that cost 16%

Shopify's quarter, on its own terms, was excellent. Revenue rose 32% to $3.74 billion from $2.84 billion a year earlier. Gross profit reached $1.78 billion. Operating income jumped 66% to $568 million, against an estimate of about $523.9 million. Free cash flow surged 61% to $816 million, a 22% free-cash-flow margin against 18% a year earlier. Net income reached $462 million, or 36 cents per share, up from $264 million a year earlier, and adjusted EPS of $0.49 beat the roughly $0.48 consensus. So why did the stock tumble roughly 16% in premarket trading? Because the miss was concentrated exactly where growth investors are most sensitive. Revenue of $3.74 billion came in just short of the $3.75 billion consensus — Shopify's first revenue miss since 2022. Gross merchandise volume grew 29% to $119.15 billion, a deceleration from 32% the prior quarter and short of the roughly $120.08 billion estimate. Subscription Solutions revenue of $836 million, up 20%, trailed estimates of roughly $850–855 million. Merchant Solutions, by contrast, surged 35% to $2.91 billion, beating the $2.88 billion estimate. In other words: the transaction engine beat, the subscription engine — the steadier, more predictable revenue stream — missed, and growth in the headline volume measure slowed. For a stock priced for flawless execution, that combination was enough.

3. The lesson: beats are relative, and guidance is the tiebreaker

Put the two reports side by side and the pattern is unmistakable:

- Pfizer beat revenue by about $0.71 billion and adjusted EPS by about $0.14, then raised guidance on both lines. The market got a better present and a better future in the same release.

- Shopify beat operating income, free cash flow and adjusted EPS — but missed revenue, GMV and subscription revenue, the three forward-looking growth signals. The market got a better present on profits and a slightly worse future on growth, and it punished the future.

- Guidance separated them further. Pfizer lifted its full-year ranges outright. Shopify guided fourth-quarter revenue growth in the low-thirties percentage range year over year, with gross-profit dollar growth at a high-twenties rate — solid, but not the acceleration that would have erased the Q3 miss.

For readers, the practical checklist from this morning is simple: read revenue against consensus before celebrating a profit beat; read subscription/recurring revenue separately from transaction revenue; read GMV growth against the prior quarter, not just the prior year; and treat a raised full-year guide as stronger evidence than any single quarter's beat. A company can grow 32% and still disappoint, and a company facing patent cliffs can still rally — because in earnings season, the only number that matters is the one nobody had already counted on.

FAQ

Did Pfizer beat expectations? Yes — revenue of $16.58 billion beat about $15.87 billion expected, and adjusted EPS of $0.87 beat about $0.73 expected; Pfizer also raised full-year guidance.

Why did Pfizer's reported EPS fall if adjusted EPS beat? Reported diluted EPS fell 9% to $0.56, reflecting charges including a $650 million R&D charge tied to the Innovent deal; adjusted EPS excludes such items.

Did Shopify miss earnings? No — Shopify beat on operating income, free cash flow and adjusted EPS ($0.49 vs about $0.48), but missed on revenue ($3.74 billion vs $3.75 billion expected) and subscription revenue.

Why did Shopify fall about 16% before the open despite 32% growth? Because it was its first revenue miss since 2022, GMV growth slowed to 29% from 32%, and subscription revenue missed estimates — the growth signals traders price most heavily.

What did Shopify guide for Q4? Revenue growth in the low-thirties percentage range year over year, gross-profit dollar growth at a high-twenties rate, and a free-cash-flow margin consistent with Q4 2025.

Our earnings-reading guide is here: https://zimbuck.com/blogs/980/How-to-Read-a-Stock-Earnings-Report-Revenue-EPS-Margins — and the Zimbuck News page is here: https://zimbuck.com/pages/zimbucknews with discussion at https://zimbuck.com/groups/zimbuckmarketnews . Pfizer's Q3 report as covered is here: https://skn-finance.com/skn-pfizer-raises-2026-forecasts-after-q3-earnings-beat-eliquis-and-oncology-portfolio-support-growth-beyond-covid/ and Shopify's Q3 report as covered is here: https://www.fool.com/investing/2026/11/03/shopify-operating-income-jumps-66-rapid-earnings-r/ . This is market news and general information only, not financial advice. Join Zimbuck at https://zimbuck.com to follow more earnings coverage.